Search research articles
Contact Us
Filters
Showing results (211-220 of 268) with videos related to
Page
of 27
Sort By:
European Journal of Endocrinology
|
March 29, 2020
Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
Annamaria Colao, Marcello D Bronstein, Thierry Brue, et al.
European Journal of Endocrinology
|
December 6, 2019
Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease
John Newell-Price, Rosario Pivonello, Antoine Tabarin, et al.
Pituitary
|
January 9, 2020
The tale in evolution: clarity, consistency and consultation, not contradiction and confusion
Ken K Y Ho, Maria Fleseriu, John Wass, et al.
Clinical Endocrinology
|
August 30, 2019
Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study
Maria Fleseriu, Stephan Petersenn, Beverly M K Biller, et al.
Neurosurgery
|
September 17, 2016
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Patients With Nonfunctioning Pituitary Adenomas: Executive Summary
Manish K Aghi, Clark C Chen, Maria Fleseriu, et al.
Journal of the Endocrine Society
|
November 29, 2024
Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol
John Newell-Price, Maria Fleseriu, Rosario Pivonello, et al.
European Journal of Endocrinology
|
September 23, 2022
Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline
Eystein S Husebye, Frederik Castinetti, Sherwin Criseno, et al.
Pituitary
|
June 20, 2020
Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic-an international perspective
Maria Fleseriu, Michael Buchfelder, Justin S Cetas, et al.
BMC Endocrine Disorders
|
April 4, 2016
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
Marcello D Bronstein, Maria Fleseriu, Sebastian Neggers, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
|
July 13, 2012
Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated IGF-1 but normal glucose-suppressed growth hormone
Sreevidya K Subbarayan, Maria Fleseriu, Murray B Gordon, et al.
Page
of 27
Search research articles
Search
Showing results (211-220 of 268) with videos related to
Sort By:
Page
of 27
European Journal of Endocrinology
|
March 29, 2020
Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
Annamaria Colao, Marcello D Bronstein, Thierry Brue, et al.
European Journal of Endocrinology
|
December 6, 2019
Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease
John Newell-Price, Rosario Pivonello, Antoine Tabarin, et al.
Pituitary
|
January 9, 2020
The tale in evolution: clarity, consistency and consultation, not contradiction and confusion
Ken K Y Ho, Maria Fleseriu, John Wass, et al.
Clinical Endocrinology
|
August 30, 2019
Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study
Maria Fleseriu, Stephan Petersenn, Beverly M K Biller, et al.
Neurosurgery
|
September 17, 2016
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Patients With Nonfunctioning Pituitary Adenomas: Executive Summary
Manish K Aghi, Clark C Chen, Maria Fleseriu, et al.
Journal of the Endocrine Society
|
November 29, 2024
Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol
John Newell-Price, Maria Fleseriu, Rosario Pivonello, et al.
European Journal of Endocrinology
|
September 23, 2022
Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline
Eystein S Husebye, Frederik Castinetti, Sherwin Criseno, et al.
Pituitary
|
June 20, 2020
Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic-an international perspective
Maria Fleseriu, Michael Buchfelder, Justin S Cetas, et al.
BMC Endocrine Disorders
|
April 4, 2016
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
Marcello D Bronstein, Maria Fleseriu, Sebastian Neggers, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
|
July 13, 2012
Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated IGF-1 but normal glucose-suppressed growth hormone
Sreevidya K Subbarayan, Maria Fleseriu, Murray B Gordon, et al.
Page
of 27